InhibitorSelect TLR Signaling Pathway Panel

Cell permeable: yes

Primary Target
Major hubs involved in TLR signaling cascade

Toxicity: Irritant (B)

A panel containing 16 potent, selective and cell-permeable inhibitors that is useful for the study of TLR signaling: 1 mg of TIRAP Inhibitor Peptide, Cell-Permeable (>Cat. No. 613570), 10 mg of IL-1R Antagonist (>Cat. No. 407616), 5 mg of Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor (Cat. No. 407601), 1 mg of (5Z)-7-Oxozeaenol, Curvularia sp. (Cat. No. 499610), 10 mg of BX-795 (Cat. No. 204001), 5 mg of NBD-Binding Peptide II, Cell Permeable, CTP-NBD (Cat. No. 480026), 25 mg of Cdc42/Rac1 GTPase Inhibitor, ML141 (Cat. No. 217708), 5 mg of PKR Inhibitor (Cat. No. 527450), 5 mg of LY294002 (Cat. No. 440202), 5 mg of U0126 (Cat. No. 662005), 1 mg of IKK Inhibitor VII (Cat. No. 401486), 10 mg of BAY 11-7082 (Cat. No. 196870), 1 mg of SB 203580 (Cat. No. 559389), 5 mg of SP600125 (Cat. No. 420119), 10 mg of STAT3 Inhibitor III, WP1066 (Cat. No. 573097), and 10 mg of MG-132 (Cat. No. 474787). Also provided with 15 ml of anhydrous DMSO (Cat. No. KP31817).

Aksoy, E., et al. 2012. Nat. Immunol.13, 1045.
Kondo, T., et al. 2012. Trends Immunol.33, 449.
Kawai, T. and Akira, S., 2010. Nat. Immunol.11, 373.
Kong, L. and Ge, B.X., 2008. Cell Res.18, 745.
Gilliet, M., et al. 2008. Nat. Rev. Immunol.8, 594.
Verstrepen, L., et al. 2008. Cell. Mol. Life Sci.65, 2964.
Wong, C.K., et al. 2007. Am. J. Respir. Cell Mol. Biol.37, 85.
Kawai, T. and Akira, S., 2007. Trends Mol. Med.13, 460.

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C) each inhibitor. Each inhibitor solution is stable for up to 3 months at -20°C.

Please refer to information provided on the CD for reconstitution information of individual inhibitors.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany